Louisiana is currently home to 908 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Orleans, Baton Rouge, Shreveport and Metairie. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
STRIVE Post-Market Registry Study
NCT04302272
Recruiting
This is a single-arm, prospective, multi-center, Registry study to evaluate the long-term safety and effectiveness of the Spiration Valve System (SVS) for the treatment of severe emphysema in a post-market setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: LSU Health Shreveport, Shreveport, Louisiana
Conditions: Emphysema
Register for Updates
Pulmonary Hypertension Association Registry
NCT04071327
Recruiting
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH a... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
07/28/2025
Locations: Ochsner Medical Center, Jefferson, Louisiana
Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
Register for Updates
Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Open Wounds
NCT07041177
Recruiting
This is a prospective case series evaluating the efficacy and safety of NeoThelium FT Amnion Skin Graft in the Mangement of Open Wounds
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: MedCentris of Hammond, Hammond, Louisiana
Conditions: Open Wound
Register for Updates
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738
Recruiting
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Research Site, Alexandria, Louisiana
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163
Recruiting
This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/25/2025
Locations: Accurate Clinical Research, Lake Charles, Louisiana
Conditions: Systemic Lupus Erythematosus
Register for Updates
Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction
NCT01526681
Recruiting
This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgroups within the registry.
Gender:
ALL
Ages:
All
Trial Updated:
07/25/2025
Locations: Sensation-NOW: Advanced Reconstructive Care, LLC, Metairie, Louisiana
Conditions: Peripheral Nerve Injuries
Register for Updates
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868
Recruiting
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Local Institution - 0286, Covington, Louisiana
Conditions: Breast Neoplasms
Register for Updates
PerQdisc Traditional Feasibility Trial.
NCT06860867
Recruiting
This is a traditional feasibility study (TFS) study to evaluate the safety and effectiveness of the PerQdisc. The study is prospective, multicenter, and open label. After a screening period, qualified participants will be enrolled and treated with the PerQdisc. Patients will not be blinded to their treatment. Participants will then complete the safety follow-up period.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
07/24/2025
Locations: Spine Institute of Louisiana, Shreveport, Louisiana
Conditions: Discogenic Low Back Pain
Register for Updates
Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS
NCT05737121
Recruiting
This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, multi-center, single-dose, pharmacodynamic study designed to evaluate the efficacy and safety of the combination product (VNX001) versus placebo and its individual components (heparin sodium and lidocaine hydrochloride (HCl)) for the reduction of bladder pain in patients with interstitial cystitis (IC) / bladder pain syndrome (BPS), Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Southern Clinical Research Associates LLC, Metairie, Louisiana
Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Register for Updates
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
NCT05378425
Recruiting
This is a Phase 1,open-label, multi-center, first-in-human, 2-part (Part 1: dose escalation and Part 2: expansion) study, evaluating multiple doses and schedules of intravenously (IV) administered NTX-1088, with or without pembrolizumab, in patients with advanced solid malignancies (i.e., locally advanced or metastatic).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Ochsner Clinic Foundation, New Orleans, Louisiana
Conditions: Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor
Register for Updates
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
NCT04071223
Recruiting
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and sympto... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: East Jefferson General Hospital, Metairie, Louisiana
Conditions: Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
Register for Updates
Product Surveillance Registry
NCT01524276
Recruiting
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.
Gender:
ALL
Ages:
All
Trial Updated:
07/24/2025
Locations: Not set, New Orleans, Louisiana
Conditions: Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder
Register for Updates